Showing results (121-130 of 186) with videos related to

Sort By:
Pageof 19
Blood|August 13, 2010
Conventional and pretargeted radioimmunotherapy using bismuth-213 to target and treat non-Hodgkin lymphomas expressing CD20: a preclinical model toward optimal consolidation therapy to eradicate minimal residual diseaseSteven I Park, Jaideep Shenoi, John M Pagel, et al.
British Journal of Haematology|February 8, 2020
Pembrolizumab with R-CHOP in previously untreated diffuse large B-cell lymphoma: potential for biomarker driven therapyStephen D Smith, Brian G Till, Mazyar S Shadman, et al.
American Journal of Hematology|April 4, 2020
A phase II trial evaluating the efficacy of high-dose Radioiodinated Tositumomab (Anti-CD20) antibody, etoposide and cyclophosphamide followed by autologous transplantation, for high-risk relapsed or refractory non-hodgkin lymphomaVictor A Chow, Joseph G Rajendran, Darrell R Fisher, et al.
Journal of Cellular and Molecular Medicine|December 1, 2022
Predictors of response to axicabtagene-ciloleucel CAR T cells in aggressive B cell lymphomas: A real-world studyLorenzo Iovino, Qian Vicky Wu, Jenna Voutsinas, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|July 7, 2011
Mantle cell lymphoma international prognostic index but not pretransplantation induction regimen predicts survival for patients with mantle-cell lymphoma receiving high-dose therapy and autologous stem-cell transplantationLihua E Budde, Katherine A Guthrie, Brian G Till, et al.
Leukemia & Lymphoma|July 11, 2022
Predictors of cytopenias after treatment with axicabtagene ciloleucel in patients with large B-cell lymphomaLorena Panaite, Qian Vicky Wu, Jenna Voutsinas, et al.
Blood Advances|November 17, 2022
Efficacy, safety, and molecular response predictors of oral ixazomib and short-course rituximab in untreated iNHLSolomon A Graf, Ryan C Lynch, Chaitra S Ujjani, et al.
Clinical Lymphoma, Myeloma & Leukemia|November 5, 2023
Pembrolizumab With R-CHOP in Previously Untreated DLBCL: Sustained, High Efficacy, and Safety With Long-Term Follow-UpCarrie Ho, Ajay K Gopal, Brian G Till, et al.
Journal of Nuclear Medicine : Official Publication, Society of Nuclear Medicine|March 15, 2020
Biokinetics of Radiolabeled Monoclonal Antibody BC8: Differences in Biodistribution and Dosimetry Among Hematologic MalignanciesManuela Matesan, Darrell R Fisher, Roger Wong, et al.
Clinical Lymphoma, Myeloma & Leukemia|April 6, 2019
Outcomes of Patients With Therapy-Related MDS After Chemoimmunotherapy for Chronic Lymphocytic Leukemia Compared With Patients With De Novo MDS: A Single-Institution ExperienceJason P Cooper, Sirin Khajaviyan, Stephen D Smith, et al.
Pageof 19